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a  b  s  t  r  a  c  t
Introduction: The Disease Activity Score 28 (DAS28) and its versions have been used to mea-
sure rheumatoid arthritis activity, but there is no consensus about which one is the best.
Objectives: Determine the correlation among indexes (DAS28 ESR, DAS28 CRP, SDAI and CDAI)
and evaluate agreement of activity strata using different cut-off points.
Methods: Rheumatoid arthritis patients were cross-sectionally evaluated with data collec-
tion to calculate the DAS28 (ESR and CRP), SDAI and CDAI, using different cut-offs for deﬁning
remission, mild, moderate and high activity. Pearson correlations were calculated for con-
tinuous measures and agreement (kappa test) for the strata (remission, mild, moderate and
high activity).
Results: Of 111 patients included, 108 were women, age 55.6 years, 11-year disease duration.
DAS28 (ESR) was signiﬁcantly higher than DAS28 (CRP) (4.0 vs. 3.5; p < 0.001) and the values
remained higher after stratiﬁcation by age, gender, disease duration, rheumatoid factor and
HAQ. Correlations among indexes ranged from 0.84 to 0.99, with better correlation betweenements among activity strata ranged from 46.8% to 95.8%. DAS28 (CRP)SDAI  and CDAI. Agrewith  cut-off point for the remission of 2.3 underestimated disease activity by 45.8% com-
pared with DAS28 (ESR). SDAI and CDAI showed agreement of 95.8%. The four indexes were
associated with disease duration and HAQ.
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Conclusions: Although the activity indexes show good correlation, they show discrepancies
in  activity strata, thus requiring more researches to deﬁne a better index and better cut-off
points.
©  2015 Elsevier Editora Ltda. All rights reserved.
Correlac¸ão  dos  índices  de  atividade  da  artrite  reumatoide  (Disease
Activity  Score  28  medidos  com  VHS,  PCR,  Simpliﬁed  Disease  Activity
Index  e  Clinical  Disease  Activity  Index)  e  concordância  dos  estados  de








r  e  s  u  m  o
Introduc¸ão: O Disease Activity Score 28 (DAS28) e versões têm sido usados para medir ativi-
dade da artrite reumatoide (AR), mas não existe consenso sobre qual é o melhor.
Objetivos: Determinar a correlac¸ão entre os índices (DAS28 VHS, DAS28 PCR, SDAI e CDAI) e
avaliar a concordância dos estratos de atividade com o uso de diferentes pontos de corte.
Métodos: Pacientes com AR foram avaliados transversalmente com coleta de dados para
cálculo do DAS28 (VHS e PCR), SDAI e CDAI, com o uso de pontos de cortes diferentes para
deﬁnic¸ão de remissão, atividade leve, moderada e alta. Correlac¸ões de Pearson foram calcu-
ladas para medidas contínuas e concordância (teste de kappa) para os estratos (remissão,
atividade leve, moderada e alta).
Resultados: De 111 pacientes incluídos, 108 foram mulheres, média de 55,6 anos, tempo de
doenc¸a  de 11 anos. DAS28 (VHS) foi signiﬁcantemente maior do que DAS28 (PCR) (4 vs. 3,5;
p  < 0,001) e os valores permaneceram maiores após estratiﬁcac¸ão por idade, sexo, tempo
doenc¸a,  fator reumatoide e HAQ. Correlac¸ões entre índices variaram de 0,84 a 0,99, com
melhor correlac¸ão entre SDAI e CDAI. Concordâncias entre estratos de atividade variaram
de  46,8% a 95,8%. DAS28 (PCR) com ponto de corte para remissão de 2,3 subestimou ativi-
dade  da doenc¸a em 45,8% quando comparado com DAS28 (VHS). SDAI e CDAI apresentaram
concordância de 95,8%. Os quatro índices mostraram associac¸ão com tempo de doenc¸a e
HAQ.
Conclusões: Embora os índices de atividade apresentem boa correlac¸ão, mostram discrepân-
cias  nos estratos de atividade. Tornam-se necessários mais estudos para deﬁnir melhor
índice e melhores pontos de corte.
© 2015 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
The main goals to be achieved during the treatment of patients
with rheumatoid arthritis (RA) are pain relief and the strict
control of the joint inﬂammatory process. Aiming at having a
more  adequate evaluation of the inﬂammatory activity in clin-
ical trials, the American College of Rheumatology (ACR), the
European League Against Rheumatism (EULAR) and the World
Health Organization/International League Against Rheuma-
tism (WHO/ILAR) proposed a set of variables (core sets), which
included the number of tender and swollen joints, measure-
ment of pain, global assessment of disease activity by the
physician and patient, acute phase reactant and functional
measure.1–3
In the early 90s another index to measure RA activity
in clinical practice was proposed, and was called Disease
Activity Score (DAS), which considers the number of ten-
der and swollen joints, erythrocyte sedimentation rate (ESR)
and assessment performed by the patient of global healthor of disease activity.4 This original DAS uses Ritchie articu-
lar index (26 joint regions) to assess the number of painful
joints, and 44 joints to evaluate the swollen ones. Later,
the proposed DAS28 started using only 28 joints for count-
ing the swollen and tender joints5 and allowed the optional
use of C-reactive Protein (CRP) instead of ESR as an inﬂam-
matory marker.6 Since then, DAS28 was the most common
measure used to evaluate the inﬂammatory activity, both in
clinical trials and in clinical practice. However, this index
requires a complex formula including square root of Nape-
rian logarithm, requiring a technology tool for its calculation.
Therefore, more  simple indexes were later proposed: Sim-
pliﬁed Disease Activity Index (SDAI)7 and Clinical Disease
Activity Index (CDAI).8 SDAI is a measure proposed by Smolen
et al.,7 the result of which is the simple sum of the num-
ber of painful joints (28 joints), number of swollen joints (28
joints), assessment of disease activity made by the patient
in a visual analog scale from 0 to 10 cm,  evaluation of dis-
ease activity by the physician (0–10 cm)  and CRP (mg/dL). The
calculation of the CDAI is simpler because the sum does not
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Table 1 – Cut-off points of indexes DAS28, SDAI, and CDAI to deﬁne states of disease activity.
Indexes Disease remission Mild activity Moderate activity High activity
Original DAS28 (ESR)5 <2.6 2.6–3.2 >3.2–5.1 >5.1
DAS28 (ESR) Aletaha et al.16 <2.4 2.4–3.6 >3.6–5.5 >5.5
DAS28 (CRP) Inoue et al.17 <2.3 2.3–2.7 >2.7–4.1 >4.1
DAS28 (CRP) Castrejón et al.18 <2.3 2.3–3.8 >3.8–4.9 >4.9
DAS28 (CRP) Fujiwara et al.11 <1.72 1.72–2.98 >2.98–4.77 >4.77
SDAI7 <3.3 3.3–11 >11–26 >26













































The cut-off points considered to deﬁne the inﬂammatoryDAS28, Disease Activity Score (28 joints); SDAI, Simpliﬁed Disease
sedimentation rate; CRP, C-reactive protein.
ake CRP into account, only the ﬁrst four measures. Although
ndexes show good correlation with each other,7–11 DAS28
s the most validated index for measuring disease activity.
nother advantage is that it is possible to use both ESR and
RP as an inﬂammatory marker, but use of this latter marker
till requires further study, since discrepancies between ESR
nd CRP have been reported in some patients with RA, with
 trend toward higher values of ESR and lower values of
RP.12,13
All these indexes (DAS28, SDAI and CDAI) measure disease
ctivity on a continuous scale, and also allow categorizing
he patient in activity strata, using different cut-off points:
emission, mild, moderate and high activity. With the emer-
ence of several new drugs in the last 15 years to treat RA,
isease remission is a goal that shall be sought. The indexes
ut-off points that deﬁne disease remission vary in the litera-
ure. For example, the original DAS28 established that clinical
emission was deﬁned when DAS28 (ESR) was <2.6.5 In 2005,
letaha et al. proposed to lower the cut-off point to <2.4.14
s to the best cut-off point to deﬁne remission when CRP
s used in the calculation of DAS28, a value below 2.3 was
lready suggested.15,16 In 2013, Fujiwara and Kita’s study con-
luded that the best index to deﬁne clinical remission was
AS28 measured by CRP with the conventional cut-off of 2.3
educed to 1.72.10 The cut-off points for other activity strata of
he disease also vary among the indexes and this can lead to
nconsistency in the classiﬁcation of disease activity, resulting
n different practices, also affecting the comparison of studies
hen using different criteria.
Another very important point is that the possibility of
atients’ ethnic origin inﬂuences the activity indexes, making
he generalization of studies’ results inadequate. Differences
n genetic polymorphism that inﬂuences CRP levels, as well
s other genetic and cultural factors of each population, can
nﬂuence disease activity measures, requiring that studies on
he subject are developed in different populations to estab-
ish the best index. Studies comparing different versions of
AS28 were performed predominantly in Europe and Asia and
n some African-American and black African populations.
The objectives of this study were to determine a correlation
mong the most popular indicators for measuring activity of
heumatoid arthritis (DAS28 calculated with ESR, DAS28 cal-
ulated with CRP, SDAI and CDAI) and assess the agreement of
isease activity states deﬁned by the indexes using different
ut-off points of DAS28 in a sample of patients in northeastern
razil.vity Index; CDAI, Clinical Disease Activity Index; ESR, erythrocyte
Methods
Patients with RA diagnosis according to ACR criteria17 who
were followed in the outpatient’s of the Rheumatology service
of the University Hospital Walter Cantidio at the Federal
University of Ceará were sequentially invited to participate
in the study. The presence of other autoimmune diseases,
except secondary Sjogren’s syndrome, were excluded. The
study design was cross-sectional. Data collection took place
from January to December 2013. Demographic data (gender,
age, race, education level), clinical data related to RA (disease
duration since diagnosis, presence of extra-articular manifes-
tations, rheumatoid factor, medications used), were collected
from medical records.
To calculate the activity indexes of the disease (DAS28, SDAI
and CDAI), the rheumatologist on the day of consultation col-
lected the following data: count of the number of painful and
swollen joints in 28 joints (shoulders, elbows, wrists, metacar-
pophalangeal, proximal interphalangeal, knees), global health
assessment (scale 0–100) by the patient, assessment of disease
activity by the patient and physician (0–10) and inﬂamma-
tory activity markers carried out within a maximum period
of 2 weeks before the consultation (ESR and CRP). If the
patient’s condition had changed after the completion of
inﬂammatory markers, these were not considered and a
new assessment was scheduled. Patients with categorical
CRP results (positive or negative; < or >) were not considered
for calculation of indexes that take CRP into account. Lab-
oratory tests were performed at the Central Laboratory of
HUWC and the methods employed were: ESR (Sedi-System
Automation) and CRP (immunoturbidimetry ROCHE COBAS).
DAS28 was calculated with software for speciﬁc calcula-
tion of DAS, using both ESR and CRP (mg/dl), global health
assessment by the patient, and the number of tender and
swollen joints (28 joints). SDAI was calculated by adding the
number of swollen joints (0–28), number of tender joints
(0–28), evaluation of disease activity by the patient (0–10),
evaluation of disease activity by the doctor (0–10) and the
value of CRP (0.1–10 mg/dL). The result of the CDAI was
the sum of the four previous clinical measurements without
CRP.activity states are shown in Table 1. For the DAS28 calculated
with ESR, we  used the cut-off points of the original study5 and
the study of Aletaha et al.14 For the DAS28 calculated with CRP
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Mean ± SD 11.08 ± 7.3
Median (interquartile range) 10 (5.16)






Biological (anti TNF-  and abatacept) 22.5%
Current daily dose of prednisone (mg)
Mean ± SD 5.1 ± 2.2
ESR (mm/h)
Mean ± SD 29.7 ± 21.5
Median (interquartile range) 24.5 (15–38)
CRP (mg/dL)
Mean ± SD 0.9 ± 1.0
Median (interquartile range) 0.6 (0.3–1.1)
DAS28 (ESR)
Mean ± SD 4.03 ± 1.40
Median (IQ) 3.99 (3.09–4.92)
DAS28 (CRP)
Mean ± SD 3.55 ± 1.27
Median (IQ) 3.38 (2.52–4.47)
SDAI
Mean ± SD 16.53 ± 10.54
Median (IQ) 14.1 (9.05–22.4)
CDAI
Mean ± SD 15.62 ± 10.03
Median (IQ) 13.5 (8–21)
HAQ
Mean ± SD 0.98 ± 0.69
Median (IQ) 1 (0.37–1.62)
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28
(ESR), disease activity score using ESR; DAS28 (CRP), disease activ-
ity score using CRP; SDAI, Simpliﬁed Disease Activity Index; CDAI,
Clinical Disease Activity Index; HAQ, health assessment question-480  r e v b r a s r e u m a t
we  used the cut-off points proposed by Inoue et al.,15 Castre-
jon et al.16 and Fujiwara et al.10 The physical function was
assessed using the Health Assessment Questionnaire (HAQ)18
with score of 0–3, with 0 score meaning no loss of physical
function, 3, full disability.
Statistics
Paired data of continuous variables as DAS28 (ESR) and DAS28
(CRP) and SDAI and CDAI were compared using paired t-
test. To estimate correlation between the continuous values
of DAS28 (ESR), DAS28 (CRP), SDAI, CDAI and HAQ Pearson’s
correlation coefﬁcient was used. To compare the averages,
Kruskal Wallis and Mann Whitney tests were used. The
agreement between the inﬂammatory activity states (remis-
sion, mild, moderate and high activity) was determined by
kappa test. The level of statistical signiﬁcance was 0.05.
Statistical analysis was performed using STATA version 9.0
software.
Results
A total of 111 patients were studied, predominantly female
(108 women and 3 men), most of them of white/brown race
(62%) with a mean age of 55.5 years (SD = 12.9) and duration
of disease of 11.08 years (SD = 7.3) (Table 2). Rheumatoid fac-
tor was positive in 84.1% of the sample and most made use
of methotrexate and/or leﬂunomide (95.5% and 71.2%). The
mean (± SD) and median (interquartile range 25–75) values
of DAS28 (ESR), DAS28 (CRP), SDAI, CDAI and HAQ are also
shown in Table 2. Mean DAS28 (ESR) was statistically higher
than mean DAS28 (CRP) (p < 0.001) and also that of SDAI was
statistically higher than CDAI (p < 0.001). The calculation of
the indexes using CRP was done with 96 of the 111 patients
because 15 patients did not get the proper dosage of CRP, only
of ESR.
The mean DAS28 (ESR), DAS28 (CRP), SDAI and CDAI
were also evaluated by age strata (<40, 40 to <50, 50 to
<60 and ≥60 years), disease duration (≤5, >5–10, >10–20,
>20 years), gender, rheumatoid factor (positive, negative),
and HAQ (0–1, >1–2, >2–3) (Table 3). The values of the four
activity indexes were statistically different for each stra-
tum of disease duration, with the highest values after 20
years of disease, and then with ≤5 years of disease. The
average values were also signiﬁcantly different for HAQ stra-
tum, with progressively increasing values as HAQ score range
increased.
Correlations between DAS28 (ESR), DAS28 (CRP), SDAI
and CDAI were all statistically signiﬁcant (p < 0.0001). Very
strong correlations (>0.90) were observed among DAS28 (ESR)
and DAS28 (CRP) (0.92), DAS28 (CRP) and SDAI (0.93), DAS28
(CRP) and CDAI (0.92) and between SDAI and CDAI (0.99).
Strong correlations (between 0.6 and 0.9) were observed
when comparing DAS28 (ESR) with SDAI and CDAI (0.84).
Regular correlations (0.3–0.6) were observed comparing HAQ
with DAS28 (ESR) (0.50), DAS28 (CRP) (0.48), SDAI and CDAI
(both 0.53).
When indexes were categorized by activity strata of the
disease (remission, mild, moderate and high activity), the
naire.
Comparing DAS28 (ESR) with DAS28 (CRP) and SDAI with CDAI, the
level of statistical signiﬁcance was <0.001.
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Table 3 – Values (median ± SD) of DAS28 (ESR), DAS28
(CRP), CDAI and SDAI by strata of age, disease time,










<40 years 3.7 ± 1.6 3.6 ± 1.3 14.9 ± 11.0 14.4 ± 11.0
40–49 years 3.8 ± 1.4 3.6 ± 1.3 16.0 ± 10.5 15.2 ± 10.1
50–59 years 4.3 ± 1.3 3.8 ± 1.3 17.8 ± 10.7 16.8 ± 10.1
≥60 years 3.8 ± 1.4 3.3 ± 1.2 13.8 ± 9.3 13.0 ± 8.9
p NS NS NS NS
Gender:
Female 3.9 ± 1.3 3.5 ± 1.3 15.5 ± 10.0 14.7 ± 9.6
Male 5.0 ± 2.3 5.1 ± 0.6 24.6 ± 17.5 22.6 ± 15.0
p NS 0.07 NS NS
Disease time:
≤5 years 4.4 ± 1.4 4.1 ± 1.2 20.2 ± 10.7 19.0 ± 10.2
>5–10 years 3.7 ± 1.3 3.4 ± 1.2 13.9 ± 10.1 13.0 ± 9.7
>10–20 years 3.6 ± 1.3 3.1 ± 1.2 12.7 ± 9.2 12.1 ± 8.7
>20 years 5.0 ± 1.2 4.2 ± 0.8 22.8 ± 5.7 22.0 ± 5.6
p 0.007 0.003 0.0005 0.0005
Rheumatoid factor:
Positive 3.9 ± 1.3 3.6 ± 1.2 15.7 ± 9.6 14.9 ± 9.3
Negative 3.9 ± 1.7 3.5 ± 1.6 16.6 ± 14.0 15.6 ± 13.2
p NS NS NS NS
HAQ:
0–1 3.5 ± 1.2 3.1 ± 1.1 11.8 ± 8.4 11.2 ± 8.1
>1–2 4.5 ± 1.4 4.0 ± 1.3 20.8 ± 10.3 19.8 ± 9.8
>2–3 4.7 ± 1.6 4.2 ± 1.2 23.0 ± 9.7 21.6 ± 8.9
p 0.001 0.001 0.0001 0.0001
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28
(ESR), disease activity score using ESR; DAS28 (CRP), disease activity

























istered by other authors. Although the correlationical Disease Activity Index; HAQ, health assessment questionnaire.
roportions of patients in each category according to the cut-
ff points adopted to calculate DAS28 using ESR (original5
nd Aletaha14), of DAS28 using CRP (Inoue,15 Castrejón16 and
ujiwara10) and SDAI and CDAI are presented in Table 4. Reduc-
ng the cut-off point from 2.6 to 2.4 in the calculation of
AS28 (ESR) proposed by Aletaha reduces the percentage of
atients considered to be in remission from 15.6% to 13.5%.
alculating the DAS28 with CRP and cut-off of 2.3 proposed
y Inoue and Castrejon, the percentage of patients in remis-
ion categorized as in remission increases about 2.1% and 4.2%
ompared to original DAS28 criteria (ESR) and Aletaha, respec-
ively (Table 4). The reduction of the cut-off to 1.72 proposed
y Fujiwara makes this criterion more  stringent for consider-
ng remission because it reduces from 15.6% (DAS28 ESR) to
.3% in this category. Of all the indexes were analyzed and
resented in Table 4, the cut-off points of SDAI and CDAI to
eﬁne clinical remission are the most stringent, reducing from
5.6% through original DAS28 (ESR) calculation to 4.2%. The
bsence of CRP in the calculation of CDAI does not change
nything at all in terms of remission criteria when compared
o the SDAI. The percentage of patients in the categories
f mild and moderate activity has greater variation among
ndexes than categories at the extremes (remission and high
ctivity). 5;5 5(6):477–484 481
The agreements among activity strata (remission, mild,
moderate and high activity) of different indexes and on using
different cut-off points are shown in Table 5. The best agree-
ment of categories observed was between SDAI and CDAI
(95.8%). Only one patient was in a lower category when
CDAI deﬁnition was used. When original DAS28 (ESR) was
compared with the original DAS28 (ESR) proposed by Ale-
taha, agreement of activity strata was observed in 83.3% of
patients (80/96) with 14 patients (14.6%) falling to a lower
category (underestimated activity) when using Aletaha crite-
ria (Table 6). When original DAS28 (ESR) was compared with
DAS28 (CRP) by Inoue, Castrejon and Fujiwara, the best agree-
ment was with Fujiwara criteria (67.7%). The cut-off points
suggested by Castrejón underestimated the activity in almost
half of the patients (45.8%), while those by Inoue and Fujiwara
underestimated by 16.6%. The proportions of overestimated
categories by Castrejon, Inoue and Fujiwara were, respectively,
7.3%, 20.8% and 14.6%. Comparing indexes that use CRP to cal-
culate the DAS28, the best agreement was that between what
was proposed by Inoue and Fujiwara (71.8%), with Fujiwara
overestimating the strata in 11 patients (11.4%) and underes-
timating in 16 patients (16.7%). The other agreements between
multiple comparisons performed ranged from 46.8% to
67.7%.
Discussion
With the growing and urgent need for assessment of rheuma-
toid arthritis activity not only in clinical practice but also
in the evaluation of efﬁcacy of new treatments in clinical
trials, it is increasingly important to have instruments to mea-
sure disease activity as accurately as possible. Some indexes
have been proposed in recent decades; however, they still
have properties that need better validation, since they were
tested in speciﬁc populations.4–16 There are two  main ways
to compare the rates between them: (1) as continuous meas-
ures, comparing means and medians in the same patients
and (2) as categorical measures (remission, mild, moder-
ate and high activity) and comparing the agreement among
strata.
In the present study, we analyzed DAS28 calculated with
ESR and CRP, SDAI and CDAI as continuous variables, and
also compared the four strata to each other according to the
criteria originally proposed5 and more  recently by Aletaha14
for the calculation of DAS28 using ESR; the criteria were
proposed for DAS28 using CRP according to three studies
(Inoue,15 Castrejón16 and Fujiwara10) and SDAI and CDAI.
The ﬁrst observation in this study, corroborated by several
other studies,8,13,16,19–21 is that the values of DAS28 with ESR
are higher than the values of DAS28 by CRP, even when
stratiﬁed by age groups, disease duration, rheumatoid fac-
tor, gender and HAQ score. Therefore, the activity of the
disease may be underestimated when using DAS28 with
CRP instead of DAS28 with ESR. The excellent correlation
between the indexes observed in our study was also reg-
13,15,21–23between the two indexes has been very high (92%), the cor-
relation in the four activity strata comparing the original
DAS28 (ESR) with DAS28 (CRP) with different cut-off points
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Table 4 – Proportion of patients in remission, mild, moderate and high activity according to the scores of DAS28 (ESR),
DAS28 (CRP), SDAI and CDAI.
Remission Mild activity Moderate activity High activity
Original DAS28 (ESR) 15.6% 12.5% 50.0% 22.9%
DAS28 (ESR) Aletaha et al. 13.5% 28.1% 36.5% 21.9%
DAS28 (CRP) Inoue et al. 17.7% 13.5% 37.5% 31.3%
DAS28 (CRP) Castrejón et al. 17.7% 43.7% 21.9% 16.7%
DAS28 (CRP) Fujiwara et al. 6.3% 30.2% 43.7% 19.8%
SDAI 4.2% 30.2% 48.9% 16.7%
CDAI 4.2% 31.3% 44.8% 19.7%
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28 (ESR), disease activity score using ESR; DAS28 (CRP), disease activity score
using CRP; SDAI, Simpliﬁed Disease Activity Index; CDAI, Clinical Disease Activity Index.
Table 5 – Proportions of agreement and kappa coefﬁcients among DAS28 (ESR), DAS28 (CRP), SDAI, and CDAI by strata of
disease activity.
Kappa coefﬁcient Agreement
Original DAS28 (ESR) vs. DAS28 (ESR) Aletaha 0.76 83.3%
Original DAS28 (ESR) vs. DAS28 (CRP) Inoue 0.46 62.5%
DAS28 (ESR) original vs. DAS28 (CRP) Castrejón 0.31 46.8%
Original DAS28 (ESR) vs. DAS28 (CRP) Fujiwara 0.53 67.7%
Original DAS28 (ESR) vs. SDAI 0.46 63.5%
Original DAS28 (ESR) vs. CDAI 0.44 61.5%
DAS28 (CRP) Inoue vs. DAS28 (CRP) Castrejón 0.42 55.2%
DAS28 (CRP) Inoue vs. DAS28 (CRP) Fujiwara 0.61 71.8%
DAS28 (CRP) Inoue vs. SDAI 0.38 56.2%
DAS28 (CRP) Inoue vs. CDAI 0.42 58.3%
DAS28 (CRP) Castrejón vs. DAS28 (CRP) Fujiwara 0.45 60.4%
DAS28 (CRP) Castrejón vs. SDAI 0.38 55.2%
DAS28 (CRP) Castrejón vs. CDAI 0.35 53.1%
SDAI vs. CDAI 0.93 95.8%
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28 (ESR), disease activity score using ESR; DAS28 (CRP), disease activity score
ease using CRP; SDAI, Simpliﬁed Disease Activity Index; CDAI, Clinical Dis
ranged from 46.8% to 62, 5% of patients. Therefore, an excel-
lent correlation does not necessarily mean good agreement
between the categories of activity. For instance, the criteria
proposed by Castrejón et al. underestimate the level of activ-
ity in almost half of the patients. The study by Tamhane
et al., comparing original DAS28 (ESR) with DAS28 (CRP) by
Inoue and Castrejon, also found an underestimation of dis-
ease activity in 40% of patients when the CRP was used.13
This can be explained by lowering of the cut-off point and
expansion of the range of mild activity and reduction of the





Remission (original) 13 2 
Mild activity (original) 0 12 
Moderate activity (original) 0 13 
High activity (original) 0 0 
Total 13 27 
ESR, erythrocyte sedimentation rate; DAS28 (ESR), disease activity score usActivity Index.
cut-off for high activity, causing a greater number of patients
to migrate from higher categories to lower ones. Impor-
tantly, Castrejón et al.16 estimated these cut-off points in a
population of patients with recent-onset RA (median dura-
tion of disease in the ﬁrst visit: 6 months; IQ 3.6–9 months).
The population tested in this study was of patients with long-
term RA (mean: 11.08 ± 7.3 years; median: 10 years; IQ: 5–16
years) and the study by Tamhane et al.13 had an average of
6.6 ± 9.3 years (median: 1.8 years; IQ: 0.8–9.3). When we  cate-
gorize the time of disease in groups (≤5 years, >5–10 years;
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10–20 years and >20 years) the average values of all eval-
ated indexes were statistically different, with the highest
alues at the extremes of age. We can conclude that the
uration of disease can inﬂuence the disease activity indexes
nd therefore validation of a particular index should take
he time of the disease into consideration. The cut-off points
roposed by Castrejon et al.16 may not apply to patients
ith long-term disease. The cut-offs of DAS28 (CRP) by Inoue
nd Fujiwara were established in a population of patients
ith long-standing RA (about 10 years) and both underes-
imated the level of activity in only 16.6% when compared
ith original DAS28 (ESR), and overestimated in 20.8% and
4.6%, respectively. Analyzing these properties, it appears that
he reduction of all cut-off points for the four strata pro-
osed by Fujiwara is closer to the original DAS28 criteria
ESR).
SDAI and CDAI correlated with DAS28 (ESR) of 0.84, and
he ﬁrst two with each other of 0.99. In the original study
f SDAI the correlation with DAS28 (ESR) was 0.90.7 Sta-
istical validity excluding CRP from SDAI was very much
ested in the original study of CDAI.8 In several analyses
ade between SDAI and CDAI, the values correlated almost
erfectly and the correlations between SDAI or CDAI with
riginal DAS28 (ESR) ranged from 0.87 to 0.90. Although CRP
howed no signiﬁcant colinearity with other SDAI meas-
res, only 5% of the SDAI remained unexplained when it
xcluded CRP; in DAS28 (ESR), ESR only contributed to about
5%. Mean CDAI values are obviously smaller than the SDAI,
ince the value of CRP is suppressed in the calculation. The
egrees of agreement of this study of original DAS28 (ESR)
ith the original SDAI and CDAI were low, but the agree-
ent of SDAI with CDAI was almost perfect (95.8%). This
igh agreement reinforces that the exclusion of CRP for the
alculation of CDAI almost does not change anything in the
ssessment of disease activity level compared to SDAI. Only
 of the 96 patients analyzed disagreed regarding the stra-
um.
Deﬁning a patient as in remission can mean reduction or
ven withdrawal of some drugs in use and, therefore, the
riteria shall prevent that a patient with residual activity
eases to be properly treated (underestimation of activity), and
hall also prevent the patient from being overtreated (activity
verestimation). The deﬁnition of high activity is important,
specially for deﬁning the introduction of biological agents,
nd also for prognostic reasons, since the probability of more
apid progression is greater in patients that keep the high-
st activity. The categorization of high disease activity levels
s also an important factor for eligibility of patients in clini-
al trials. Comparing the rates tested in this study, the most
igorous for the category of remission are SDAI and CDAI.
hile 15.6% of the patients studied were classiﬁed in this
tratum by original DAS28 (ESR), only 4.2% were at this level
y SDAI and CDAI. The cut-off point used by Fujiwara for
he remission of 1.72, well below the cut-off points of the
ther indexes, classiﬁed 6.3% of patients as in remission.
egarding the deﬁnition of high activity, the index covering
ore patients in this stratum was DAS28 (CRP) by Inoue (31.3%)
nd the lowest number was SDAI and DAS28 (CRP) by Castrejon
16.7%). So, for the deﬁnition of high activity, DAS28 (CRP) by 5;5 5(6):477–484 483
Inoue was the most sensitive in the population tested in this
study.
Another interesting ﬁnding of this study is that the mean
values of the four indexes studied increased progressively
with the increase of HAQ and were statistically different. This
can be explained because the physical function can inﬂu-
ence the global health assessment and activity made by the
patient and doctor. The HAQ correlations with indexes were
very similar to other studies.7,9,14 Age, sex and rheumatoid
factor did not inﬂuence the values of the indexes stud-
ied in the present study. Although the mean values of the
four indexes were all numerically higher in men  than in
women, just for DAS28 (CRP) there was a trend toward statis-
tical difference (p = 0.07). The small number of male patients
may have inﬂuenced the statistical outcome. Some authors
suggest that the calculation of DAS28 considers the gender
and age,13,21 but this has not been established and vali-
dated.
In short, while the indexes DAS28 (ESR), DAS28 (CRP), SDAI
and CDAI correlated well with each other, they had many
discrepancies regarding the categories/strata of inﬂamma-
tory activity. Regarding the calculation of DAS28, the value
of disease activity as measured using CRP was underesti-
mated compared to the measure using ESR. Therefore, the
deﬁnition of remission and activity by a particular index
may not have the same meaning when measured by another
index.
The activity of the disease evaluated by SDAI and CDAI
showed excellent correlation and agreement, stressing that
the CRP dosage is not indispensable for activity clinical assess-
ment. Therefore, CDAI can be used instead of SDAI because its
simplicity allows its use at any time, and anywhere. Another
interesting fact is that all the indexes evaluated in the study
to measure RA activity were associated with disease dura-
tion and functional capacity, factors that should be taken into
account in the assessment of disease activity as measured by
the indexes studied.
The study has some limitations: small sample size, dif-
ferent evaluators to count number of tender and swollen
joints, and patients’ cultural and ethnic background. A larger
sample size would lead to more  patients in the four strata
of activity according to the cut-off points analyzed, which
would increase the power of conclusion of the study. The
count of painful and swollen joints may show little variability
when made by different evaluators. Ideally, all patients should
be always examined by the same observer, or the examina-
tion technique should be standardized by the evaluators and
trained previously. Patients in the study were from a public
institution of tertiary care, with low socioeconomic status,
low education and long-standing disease, characteristics that
may inﬂuence the degree of response of the components to
calculate the activity indexes, including the assessment of
health and activity status made by patients and counting of
painful joints.
Therefore, further studies are needed to establish the best
measure of disease activity, and ﬁner cut-off points, so that
the indexes more  accurately express the inﬂammatory con-
dition, and the results of the studies are comparable, taking
demographic, cultural and clinical factors into account that
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may interfere with the assessment of disease activity. Mean-
while, the choice of index to be used will depend on: the
objective of assessment (whether for use in daily practice or
in clinical trials), the desired goal (remission or therapeutic
change), the practice context (availability of technology, lab-
oratory tests, time) and personal clinician preferences. When
analyzing published studies, we  should consider which index
and which cut-off point were used for comparison. In clinical
practice, the same index with the same components for calcu-
lation should always be consistently used to allow longitudinal
comparisons in decision-making.
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